Get started
Axsome Therapeutics, Inc.Axsome Therapeutics, Inc.Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AXSM chart


Full chart

AXSM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.40 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−6.54 USD
Net income (FY)
‪−239.24 M‬ USD
Revenue (FY)
‪270.60 M‬ USD
Shares float
‪39.61 M‬
Beta (1Y)
0.55

Employees


Employees (FY)
545
Change (1Y)
+162 +42.30%
Revenue / Employee (1Y)
‪496.51 K‬ USD
Net income / Employee (1Y)
‪−438.97 K‬ USD

About Axsome Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Herriott Tabuteau
Website
axsome.com
Headquarters
New York
Founded
2012
FIGI
BBG00B6G7GL7
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AXSM news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AXSM is 90.73 USD — it has increased by 1.10% in the past 24 hours. Watch Axsome Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Axsome Therapeutics, Inc. stocks are traded under the ticker AXSM.
AXSM stock has fallen by −3.49% compared to the previous week, the month change is a −4.31% fall, over the last year Axsome Therapeutics, Inc. has showed a 27.64% increase.
We've gathered analysts' opinions on Axsome Therapeutics, Inc. future price: according to them, AXSM price has a max estimate of 180.00 USD and a min estimate of 105.00 USD. Watch AXSM chart and read a more detailed Axsome Therapeutics, Inc. stock forecast: see what analysts think of Axsome Therapeutics, Inc. and suggest that you do with its stocks.
AXSM reached its all-time high on Dec 30, 2019 with the price of 109.94 USD, and its all-time low was 1.94 USD and was reached on Dec 27, 2018. View more price dynamics on AXSM chart.
See other stocks reaching their highest and lowest prices.
AXSM stock is 6.19% volatile and has beta coefficient of 0.55. Track Axsome Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Axsome Therapeutics, Inc. there?
Today Axsome Therapeutics, Inc. has the market capitalization of ‪4.40 B‬, it has decreased by −4.33% over the last week.
Yes, you can track Axsome Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Axsome Therapeutics, Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
AXSM earnings for the last quarter are −1.34 USD per share, whereas the estimation was −1.38 USD resulting in a 3.14% surprise. The estimated earnings for the next quarter are −0.96 USD per share. See more details about Axsome Therapeutics, Inc. earnings.
Axsome Therapeutics, Inc. revenue for the last quarter amounts to ‪103.74 M‬ USD, despite the estimated figure of ‪98.37 M‬ USD. In the next quarter, revenue is expected to reach ‪117.69 M‬ USD.
AXSM net income for the last quarter is ‪−64.60 M‬ USD, while the quarter before that showed ‪−79.34 M‬ USD of net income which accounts for 18.58% change. Track more Axsome Therapeutics, Inc. financial stats to get the full picture.
No, AXSM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 545.00 employees. See our rating of the largest employees — is Axsome Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Axsome Therapeutics, Inc. EBITDA is ‪−238.39 M‬ USD, and current EBITDA margin is −65.07%. See more stats in Axsome Therapeutics, Inc. financial statements.
Like other stocks, AXSM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Axsome Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Axsome Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Axsome Therapeutics, Inc. stock shows the buy signal. See more of Axsome Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.